Deutsche Märkte öffnen in 7 Stunden 38 Minuten

Bavarian Nordic A/S (BAVA.CO)

Copenhagen - Copenhagen Echtzeitpreis. Währung in DKK
Zur Watchlist hinzufügen
356,00+0,60 (+0,17%)
Börsenschluss: 04:59PM CEST

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
https://www.bavarian-nordic.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter830

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Paul John Chaplin MSc, Ph.D.CEO & Pres9,61MN/A1967
Mr. Henrik Juuel M.Sc.CFO & Exec. VP5,07MN/A1965
Mr. Russell ThirskExec. VP & COON/AN/AN/A
Mr. Rolf Sass SørensenVP of Investor Relations & CommunicationsN/AN/AN/A
Ms. Anu Helena KernsExec. VP & Chief People OfficerN/AN/A1972
Mr. Jean-Christophe MayExec. VP & Chief Commercial OfficerN/AN/A1967
Dr. Laurence De MoerloozeExec. VP & Chief Medical OfficerN/AN/A1964
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in DKK.

Beschreibung

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Corporate Governance

Bavarian Nordic A/Ss ISS Governance QualityScore, Stand 1. Juli 2022, lautet 3. Die grundlegenden Scores sind Audit: 3, Vorstand: 5, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.